The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event

Obesity Surgery

Volumn 17, Issue 9, 2007, Pages 1199-1208

  Botella Carretero, José I ^a   Álvarez Blasco, Francisco ^a   Angeles Martinez Garcia M ^a   Luque Ramírez, Manuel ^a   San Millán, José L ^a   Escobar Morreale, Héctor F ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Bariatric surgery; C reactive protein; Hyperandrogenism; IL 18; Insulin resistance; Morbid obesity; Polycystic ovary syndrome; Weight loss

Indexed keywords

INTERLEUKIN 18;

ADULT; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; STEP WISE MULTIPLE REGRESSION; SURGICAL TECHNIQUE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; MIDDLE AGED; MORBID OBESITY; TIME;

ADULT; BARIATRIC SURGERY; FEMALE; HUMANS; INTERLEUKIN-18; MIDDLE AGED; OBESITY, MORBID; TIME FACTORS;

EID: 38549134428     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-007-9202-3     Document Type: Article

References (39)

1. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
2. Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med 1998; 104: 18S-27S.
3. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
4. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54.
5. Okamura H, Tsutsui H, Kashiwamura S et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281-312.
6. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103: 11-24.
7. Blankenberg S, Tiret L, Bickel C et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
8. Esposito K, Pontillo A, Ciotola M et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002; 87: 3864-6.
9. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-804.
10. Fischer CP, Perstrup LB, Berntsen A et al. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005; 117: 152-60.
11. Skurk T, Kolb H, Muller-Scholze S et al. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 2005; 152: 863-8.
12. Wood IS, Wang B, Jenkins JR et al. The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFalpha in human adipocytes. Biochem Biophys Res Commun 2005; 337: 422-9.
13. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004; 89: 806-11.
14. Poobalan A, Aucott L, Smith WC et al. Effects of weight loss in overweight/obese individuals and longterm lipid outcomes - a systematic review. Obes Rev 2004; 5: 43-50.
15. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
16. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8:iii-iv, 1-182.
17. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 2006; 91: 4223-31.
18. Kopp HP, Kopp CW, Festa A et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
19. Kopp HP, Krzyzanowska K, Mohlig M et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes 2005; 29: 766-71.
20. Schernthaner GH, Kopp HP, Kriwanek S et al. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocytechemoattractant-protein-1 in morbid obesity. Obes Surg 2006; 16: 709-15.
21. Vazquez LA, Pazos F, Berrazueta JR et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90: 316-22.
22. Scopinaro N. Biliopancreatic diversion: mechanisms of action and long-term results. Obes Surg 2006; 16: 683-9.
23. Rosenthal RJ, Szomstein S, Kennedy CI et al. Laparoscopic surgery for morbid obesity: 1,001 consecutive bariatric operations performed at The Bariatric Institute, Cleveland Clinic Florida. Obes Surg 2006; 16: 119-24.
24. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A, Givens JR, Haseltine FP et al, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications. 1992: 377-84.
25. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90: 6364-9.
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
27. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
28. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294: 1909-17.
29. Fontaine KR, Redden DT, Wang C et al. Years of life lost due to obesity. JAMA 2003; 289: 187-93.
30. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
31. Sugerman HJ, Wolfe LG, Sica DA et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237: 751-6.
32. Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 547-59.
33. Scopinaro N, Gianetta E, Adami GF et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996; 119: 261-8.
34. Zengin K, Taskin M, Sakoglu N et al. Systemic inflammatory response after laparoscopic and open application of adjustable banding for morbidly obese patients. Obes Surg 2002; 12: 276-9.
35. Nguyen NT, Goldman CD, Ho HS et al. Systemic stress response after laparoscopic and open gastric bypass. J Am Coll Surg 2002; 194: 557-66.
36. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
37. Blankenberg S, Luc G, Ducimetiere P et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-9.
38. McCullough PA, Gallagher MJ, Dejong AT et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest 2006; 130: 517-25.
39. Zhang YF, Yang YS, Hong J et al. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006; 29: 419-23.